IBA demonstrates its commitment to its customers by upgrading two Proteus centers with Cone Beam CT state of the art imaging system

Proton therapy

Louvain-la-Neuve, Belgium, December 17, 2020 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions, shows its commitment to the continuous development of upgrades for its proton therapy customers. Northwestern Medicine Proton Center in Chicago and the Centre Antoine Lacassagne in Nice - two well-renowned proton therapy centers with many years of operational experience.- have contracted for the Cone-Beam CT (CBCT) upgrade to their current system, on Proteus®PLUS* and Proteus®ONE* respectively. The CBCT upgrade will take place without any disruption to patient treatment.

CBCT technology is an imaging technique that allows for volumetric imaging and ensures better visualization of soft tissues. It is perfectly suited for an optimal alignment of the patient for treatment cases such as lungs, head & neck, breasts, liver, or pelvis. It also allows for better evaluation of anatomical changes throughout the course of treatment.

With 36 centers in operation, IBA has the largest and most experienced user community in proton therapy with over 100.000 patients treated in the last 20 years. This opens many opportunities to enhance the clinical performance of existing systems when new functionalities become available.

Olivier Legrain, Chief Executive Officer of IBA commented: “IBA is committed to supporting our customer base, the largest and most experienced in proton therapy. Our clinical partners want to have access to our latest technological developments, and we take pride in responding to their needs, allowing them to expand their clinical capabilities, and extend the lifetime of their equipment.”

Mark Pankuch,Director of Medical Physics at Northwestern Medicine Proton Center commented: “At Northwestern University, we have a long successful experience of upgrades with IBA since we started treating patients in 2010. We successfully added Pencil Beam Scanning to our existing Proteus®PLUS center in 2018. Thanks to an excellent collaboration with the IBA team, we completed this process in record time and without any treatment interruption, maintaining uptime of 99% throughout the entire process. We are excited to add CBCT to continuously improve the performance of our system for the many years to come.”


*** Ends ***


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

* Proteus®PLUS and Proteus®ONE are brand names of Proteus 235


For further information, please contact:

Aymeric Harmant
Global Marketing Director
+32 10 203 796


Cookies policy

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et des offres adaptés à vos centres d’intérêts.

Gérer vos préférences de cookies

Chez IBA, le respect de votre vie privée reste une priorité.

Les cookies fonctionnels garantissent le fonctionnement du site web. Ils ne peuvent pas être désactivés. En réglant vos préférences, vous pouvez activer et désactiver l’utilisation de ces cookies sur notre site web. Ces réglages ne seront valides que sur l’appareil que vous utilisez actuellement.

Cookies policies